Cancer vaccines as promising immuno-therapeutics: platforms and current progress

Liu, Jian; Fu, Minyang; Wang, Manni; Wan, Dandan; Wei, Yuquan; Wei, Xiawei

doi:10.1186/s13045-022-01247-x

Cited by 323 publications

(296 citation statements)

References 237 publications

Supporting

Mentioning

242

Contrasting

Unclassified

Order By: Relevance

“…[ 66 ]. New approaches such as formation of therapeutic cancer vaccine by combining anti-PD1 or anti-CTLA4 with peptide vaccine/tumor cell vaccine/DNA vaccine pTVG-HP plasmid/Tuberculosis vaccine BCG/Dendritic cell vaccine Sipuleucel T helps in the activation of antigen presenting cells and enhances recognition of tumor cells by T cells [ 67 , 68 ]. Other approaches include virotherapy where oncolytic virus T-VEC and IDO inhibitor in combination with check point inhibitors enhance tumor immunogenic potential [ 69 ].…”

Section: Combination Immunotherapymentioning

confidence: 99%

Immunotherapy: an alternative promising therapeutic approach against cancers

et al. 2022

View full text Add to dashboard Cite

The immune system interacts with cancer cells in multiple intricate ways that can shield the host against hyper-proliferation but can also contribute to malignancy. Understanding the protective roles of the immune system in its interaction with cancer cells can help device new and alternate therapeutic strategies. Many immunotherapeutic methodologies, including adaptive cancer therapy, cancer peptide vaccines, monoclonal antibodies, and immune checkpoint treatment, have transformed the traditional cancer treatment landscape. However, many questions remain unaddressed. The development of personalized combination therapy and neoantigen-based cancer vaccines would be the avant-garde approach to cancer treatment. Desirable chemotherapy should be durable, safe, and target-specific. Managing both tumor (intrinsic factors) and its microenvironment (extrinsic factors) are critical for successful immunotherapy. This review describes current approaches and their advancement related to monoclonal antibody-related clinical trials, new cytokine therapy, a checkpoint inhibitor, adoptive T cell therapy, cancer vaccine, and oncolytic virus. Supplementary Information The online version contains supplementary material available at 10.1007/s11033-022-07525-8.

show abstract

Section: Combination Immunotherapymentioning

confidence: 99%

Immunotherapy: an alternative promising therapeutic approach against cancers

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Therefore, in order to develop more effective strategies in TCL delivery, the optimization for clinical safety, and the combination with an additional immune agonist or adjuvant, is necessary for inducing selective activation of T cells to respond to specific tumor antigens, rather than broad activation of various immune cells, which could cause deleterious side effects [ 151 ]. It should be also emphasized that there is still work to be done in developing combination therapy and optimizing vaccine platforms before TCL-based treatment becomes a viable immune modulatory and therapeutic strategy [ 152 ].…”

Section: Therapeutic Outcomes Of Exogenous Tcl Delivery Using Various...mentioning

confidence: 99%

Activation of Cellular Players in Adaptive Immunity via Exogenous Delivery of Tumor Cell Lysates

Seong

Kim

2022

Pharmaceutics

View full text Add to dashboard Cite

Tumor cell lysates (TCLs) are a good immunogenic source of tumor-associated antigens. Since whole necrotic TCLs can enhance the maturation and antigen-presenting ability of dendritic cells (DCs), multiple strategies for the exogenous delivery of TCLs have been investigated as novel cancer immunotherapeutic solutions. The TCL-mediated induction of DC maturation and the subsequent immunological response could be improved by utilizing various material-based carriers. Enhanced antitumor immunity and cancer vaccination efficacy could be eventually achieved through the in vivo administration of TCLs. Therefore, (1) important engineering methodologies to prepare antigen-containing TCLs, (2) current therapeutic approaches using TCL-mediated DC activation, and (3) the significant sequential mechanism of DC-based signaling and stimulation in adaptive immunity are summarized in this review. More importantly, the recently reported developments in biomaterial-based exogenous TCL delivery platforms and co-delivery strategies with adjuvants for effective cancer vaccination and antitumor effects are emphasized.

show abstract

“…However, as we further our understanding of the tumour microenvironment and acknowledge that the immunosuppressive setting can have a negative effect on the function of cancer vaccines, we can use combinational treatments with check point inhibitors to allow effector T-cells to function, which may be the way forward [74,75]. Furthermore, with the aid of next-generation gene sequencing, there is the ability to detect specific antigens expressed by an individual patient in order to produce personalised vaccine therapy, putting this treatment option back in the spotlight [76]. In oesophageal cancer, the first steps in developing a cancer vaccine with the majority targeting the NYE-SO-1 tumour-associated antigen are currently being explored; multiple phase 1 trials are recruiting, and results are awaited (Table 3).…”

Section: Vaccine Technology In Antitumour Therapymentioning

confidence: 99%

Current and Future Immunotherapy-Based Treatments for Oesophageal Cancers

Evans

Pearce

et al. 2022

Cancers

View full text Add to dashboard Cite

Oesophageal cancer is a disease that causes significant morbidity and mortality worldwide, and the prognosis of this condition has hardly improved in the past few years. Standard treatment includes a combination of chemotherapy, radiotherapy and surgery; however, only a proportion of patients go on to treatment intended to cure the disease due to the late presentation of this disease. New treatment options are of utmost importance, and immunotherapy is a new option that has the potential to transform the landscape of this disease. This treatment is developed to act on the changes within the immune system caused by cancer, including checkpoint inhibitors, which have recently shown great promise in the treatment of this disease and have recently been included in the adjuvant treatment of oesophageal cancer in many countries worldwide. This review will outline the mechanisms by which cancer evades the immune system in those diagnosed with oesophageal cancer and will summarize current and ongoing trials that focus on the use of our own immune system to combat disease.

show abstract

Cancer vaccines as promising immuno-therapeutics: platforms and current progress

Cited by 323 publications

References 237 publications

Immunotherapy: an alternative promising therapeutic approach against cancers

Immunotherapy: an alternative promising therapeutic approach against cancers

Activation of Cellular Players in Adaptive Immunity via Exogenous Delivery of Tumor Cell Lysates

Current and Future Immunotherapy-Based Treatments for Oesophageal Cancers

Contact Info

Product

Resources

About